Metabolic Disease Models CROs for Non-human Primate Studies

4 contract research organizations in our directory list both Metabolic Disease Models and Non-human Primate among their capabilities, across 3 countries. 2 report GLP capability and 4 report AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.

4 CROs 2 GLP 4 AAALAC 3 countries

Metabolic Disease Models CROs for Non-human Primate Studies

Showing 4 CROs. Order rotates daily so no lab is permanently listed first.

Hamamatsu Pharma Research

JP AAALAC

AAALAC-accredited Japanese CRO specializing in nonhuman primate disease models for preclinical efficacy and proof of concept.

Metabolic Disease Models CNS Disease Models In Vivo Efficacy Non-human Primate

Oregon National Primate Research Center

US AAALAC

OHSU national primate research center supporting neuroscience, metabolic, reproductive and infectious disease research, with core services available to outside investigators.

Metabolic Disease Models CNS Disease Models In Vivo Efficacy Infectious Disease Models Non-human Primate Rhesus monkey

PharmaLegacy Laboratories

CN GLP AAALAC

Preclinical pharmacology CRO in Shanghai with specialty efficacy models in autoimmunity, inflammation, bone and orthopedics, oncology and metabolic disease, plus supporting PK/PD and exploratory toxicology.

Metabolic Disease Models Bone & Joint Models In Vivo Efficacy Inflammation Models Oncology Models Non-human Primate Dog Mouse Rabbit

Virscio

US GLP AAALAC

Translational research company using Old World primate models for ophthalmology, CNS and metabolic disease studies, with an AAALAC-accredited primate facility.

Metabolic Disease Models CNS Disease Models In Vivo Efficacy Ophthalmology Models Pharmacokinetics Non-human Primate

Questions to ask when choosing a Metabolic Disease Models in Non-human Primate CRO

  • Which metabolic models do you run in-house, and what diet, vendor and age at start do you use for DIO animals?
  • What positive control do you use (for example a GLP-1 receptor agonist), and what effect size do you typically see?
  • Do you measure body composition, food intake and energy expenditure in the same animals?
  • Do you offer hyperinsulinemic–euglycemic clamps, and in which species?
  • For MASH studies, who scores liver histology, is it blinded, and which scoring system is used?